Novocure Limited disclosed that it identified unauthorized access to certain information systems through a subsidiary in mid-August 2026, prompting the activation of its cybersecurity response plan and an internal investigation with independent forensic experts. The exposed information includes internal patient ID numbers associated with more than 1,400 U.S. patient records, though these IDs were not accompanied by names or other identifying details. Data for fewer than 50 other patients in the western U.S. included additional identifying information, and general contact information for healthcare providers and employees was also exposed. The company stated that its medical treatment devices were not accessed and its systems remain fully functional, and it does not believe the incident will have a material impact on its financial condition. Shares of Novocure have gained 3.2% since the announcement on September 1, and year to date the stock has rallied 38.8%, outperforming the industry's 10.2% growth and the S&P 500's 12.1% return.
Novocure LtdData breach affecting patient records triggers regulatory and legal risks.
Veracyte Inc
West Pharmaceutical Services Inc
Globus Medical